OncoImmunology (Jan 2021)

Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers

  • Juan-Pablo Cerapio,
  • Marion Perrier,
  • Camille-Charlotte Balança,
  • Pauline Gravelle,
  • Fréderic Pont,
  • Christel Devaud,
  • Don-Marc Franchini,
  • Virginie Féliu,
  • Marie Tosolini,
  • Carine Valle,
  • Fréderic Lopez,
  • Anne Quillet-Mary,
  • Loic Ysebaert,
  • Alejandra Martinez,
  • Jean Pierre Delord,
  • Maha Ayyoub,
  • Camille Laurent,
  • Jean-Jacques Fournie

DOI
https://doi.org/10.1080/2162402X.2021.1939518
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

γδ T lymphocytes diverge from conventional T CD8 lymphocytes for ontogeny, homing, and antigen specificity, but whether their differentiation in tumors also deviates was unknown. Using innovative analyses of our original and ~150 published single-cell RNA sequencing datasets validated by phenotyping of human tumors and murine models, here we present the first high-resolution view of human γδ T cell differentiation in cancer. While γδ T lymphocytes prominently encompass TCRVγ9 cells more differentiated than T CD8 in healthy donor’s blood, a different scenario is unveiled in tumors. Solid tumors and lymphomas are infiltrated by a majority of TCRVγnon9 γδ T cells which are quantitatively correlated and remarkably aligned with T CD8 for differentiation, exhaustion, gene expression profile, and response to immune checkpoint therapy. This cancer-wide association is critical for developing cancer immunotherapies.

Keywords